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Abstract 
Metformin is currently the first-line drug treatment for type 2 diabetes. Besides its 
glucose-lowering effect, there is interest in actions of the drug of potential relevance to 
cardiovascular diseases and cancer. However, the underlying mechanisms of action 
remain elusive. Convincing data place energy metabolism at the center of metformin’s 
mechanism of action in diabetes and may also be of importance in cardiovascular 
diseases and cancer. Metformin-induced activation of the energy-sensor AMPK is well 
documented, but may not account for all actions of the drug. Here, we summarize 
current knowledge about the different AMPK-dependent and AMPK-independent 
mechanisms underlying metformin action.  
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Introduction 
Metformin has been an important drug for treatment of type 2 diabetes (T2D) for 
decades. It isthe most widely used oral anti-hyperglycemic agent, andis currently 
recommended as first line therapy for all newly diagnosedT2D patients(American 
Diabetes Association, 2014). Metformin(N, N-dimethylbiguanide) belongs to the 
biguanide class of anti-diabetic drugs (containing two linked guanidine rings) originally 
derived fromgalegine (isoamylene guanidine), a guanidine derivative found in the 
French lilac Galegaofficinalis.Among the threebiguanidesdeveloped for diabetes therapy, 
metformin has a superior safety profile and it is well tolerated. Two other biguanides, 
phenformin and buformin, were withdrawn in the early 1970’s due to risk of lactic 
acidosis and increased cardiac mortality. The incidence of lactic acidosis with metformin 
at therapeutic doses is rare (less than 3 cases per 100.000 patient-years) and not greater 
than with non-metformin therapies. Metformin has been used widely in the treatment of 
T2Dfor over 50 years and has been found to be safe and efficacious both as 
monotherapy and in combination with other oral anti-diabetic agents and insulin. It 
offers the major clinical advantage of not inducing hypoglycemia or weight gain and 
ameliorates hyperglycemia with remarkable cardiovascular safety. Besides its use in 
T2D, there is interest in the use of metformin for the treatment of polycystic ovary 
disease,diabetic nephropathy and gestational diabetes (Viollet et al., 2012). The drug 
also has the advantage of counteracting the cardiovascular complications associated 
with diabetesas reportedin a large cohort of individuals fromthe United Kingdom 
Prospective Diabetic Study (UKPDS)(1998).Another possible benefit for metformin use 
is the association with decreased cancer risk and improved cancer prognosis (Pollak, 
2012b; Viollet et al., 2012). Although metformin has been used in Europe for treatment 
of hyperglycemiasince 1957 (and inthe USA sinceFDA approval in 1994), the exact 
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molecular mechanisms of itstherapeutic action remain obscure. In this review, we 
summarize what is currently known about these molecular mechanismsin the context of 
classic use for T2D and also for possible novel areas of therapeutic application. 
 
Pharmacokinetics and pharmacogenomics 
Pharmacokinetics of metformin 
 The optimal oral metformin dose for many diabetic patients is ~2g/day. After a 
single oral dose, metformin is rapidly distributed tomany tissues following partial 
absorption by the small intestine, but the luminal concentration in the gastrointestinal 
tract remains high. The peak plasma concentration occurs in 3 h (increasing from 1.0 to 
1.6 µg/ml [about 6 to 10 µM]after a 0.5 g dose and to ~3 µg/ml [about18 µM]after a 1.5 
g dose) with a mean plasma half-life of about 20 hours (Tucker et al., 1981).When the 
human metformin dose of 20 mg/kg/day orally is translated to the mouse equivalent 
dose of 250 mg/kg/day, according to the normalization to body surface area, murine 
plasma levels of metformin of up to 1.7 µg/ml(about 10 µM) are achieved(Memmott et 
al., 2010). This is in the range achieved when conventional anti-diabetic doses are used 
in humans(Tucker et al., 1981). Biodistribution studies in mice using 14C-labelled 
metformin showed accumulation mainly in the gastrointestinal tract, kidney and 
liver(Wilcock and Bailey, 1994). It is important to notethat being supplied directly by 
blood coming from the portal vein, the liver may contain a concentration of orally 
administered metformin substantially higher than in the general circulation and other 
organs(Wilcock and Bailey, 1994). Metformin liver concentrations of greater than 180 
µmol/kgwet weight and 250 µmol/kgwet weight in normal and diabetic rodents, 
respectively, can be achieved after a single dose of 50 mg/kg (Wilcock and Bailey, 1994). 
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Cellular uptake of metformin 
Metformin is an unusually hydrophilic drug that mostly exists in a positively 
charged protonated form under physiological conditions. These physicochemical 
properties make rapid and passive diffusion through cell membranes unlikely. Indeed, 
transport of metformin involves an active uptake process viasolute carrier organic 
transporters. The intestinal absorption of metformin is primarily mediated by the 
plasma membrane monoamine transporter (PMAT, SLC29A4 gene), which is localized on 
the luminal side of enterocytes. Organic cation transporter1 (Oct1, SLC22A1 gene) is 
expressed on the basolateral membrane of enterocytes and may be responsible for the 
transport of metformin into the interstitial fluid(Gong et al., 2012). The primary 
mediator of hepatic metformin uptake is OCT1 and possibly OCT3 (SLC22A3 gene), 
expressed at the basolateral membrane of hepatocytes (Gong et al., 2012). The clearance 
of metformin is dependent on renal elimination as metformin does not undergo relevant 
biotransformation in the liver or biliary excretion. In the kidney, metformin is taken up 
into renal epithelial cells by OCT2 (SLC22A2 gene), expressed on the basolateral 
membrane, and excreted into the urine via multidrug and toxin extrusion 1 and 2 
(MATE1 geneSLC47A1 andMATE2 SLC47A2 genes). 
 
Pharmacogenomics of metformin 
Considerable inter-individual heterogeneity in clinical efficacy and the 
pharmacokinetic disposition of metforminhas been reported in the treatment of diabetic 
patients. This may be explained by variability in genetic polymorphisms of cation 
transporters. It was first reported that individuals carrying polymorphisms of the OCT1 
gene SLC22A1 display an impaired effect of metformin in lowering blood glucose levels, 
consistent with the great reduction of hepatic metformin uptake observed in OCT1 -/- 
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mice(Shu et al., 2007).However, these results have not been confirmed in the long-term 
follow-up of a large observational cohort of patients treated with metformin(Zhou et al., 
2009). Conversely, variants in the MATE1 gene SLC47A1 enhance the effect of metformin 
on glycated hemoglobin (HbA1c) and glucose tolerance in T2D patients(Becker et al., 
2009). In MATE 1 -/- mice, urinary excretion of metformin is significantly 
decreased,suggesting that MATE1 is essential for renal clearance of the drug(Tsuda et 
al., 2009). Among new candidate genetic determinants of metformin response, single 
nucleotide polymorphisms have been identified in the AMPK subunit genes, PRKAA1, 
PRKAA2 and PRKAB2 and the LKB1 gene, STK11(Jablonski et al., 2010). In addition, a 
recent genome-wide association study showed association between a large locus on 
chromosome 11, encompassing several genes, and glycemic variability in response to 
metformin therapy(Zhou et al., 2011). This locus includes the ataxia telangiectasia 
mutated (ATM) geneand it was suggested as the most likely candidate given its 
association with insulin resistance and T2D. However, additional studies are needed to 
clearly delineate genetic influences on the clinical response to metformin. 
 
Metformin and mitochondrial oxidative phosphorylation 
It is generally accepted that actions of metformin (and other biguanides) on 
mitochondria underlie most of the pleiotropic effects of the drug. This emerging 
consensus originates from two seminal papers published in 2000 reporting that 
metformin decreases cellular respiration by a mild and specific inhibition of the 
respiratory-chain complex 1 (NADH:ubiquinoneoxidoreductase) without affecting any 
other steps of the mitochondrial machinery (El-Mir et al., 2000; Owen et al., 2000). 
However, reviewing early mechanistic studies, the first observation reporting effects of 
biguanide derivatives on mitochondrial oxidative phosphorylation (OXPHOS) comes 
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from the pioneering work of Hollunger in the 50’s that linked the increase in glycolysis 
induced by this class of molecules to the inhibition of cellular respiration (Hollunger, 
1955). Later, high concentrations of various biguanide derivatives were found to 
specifically reduce NADH but not succinate oxidation in submitochondrial particles, 
assigning the inhibitory effect of these compounds on OXPHOS to the complex 1 of the 
mitochondrial electron transport chain (ETC). Thus, the concept that members of the 
biguanide family, including phenformin and metformin, exert many of their actions 
though modulation of mitochondrial energetics is not a recent proposal. During the last 
decade, the specific inhibition of the mitochondrial respiratory-chain complex 1 by 
metformin was confirmed in many cellular models, including rat, mouse and human 
primary hepatocytes (El-Mir et al., 2000; Owen et al., 2000; Stephenne et al., 
2011)hepatoma and adrenocortical carcinoma immortalized cell lines (Guigas et al., 
2004; Hirsch et al., 2012; Kim et al., 2013), skeletal muscle homogenates (Brunmair et 
al., 2004), endothelial cells (Detaille et al., 2005), pancreatic beta cells (Hinke et al., 
2007), neurons (El-Mir et al., 2008), peripheral blood mononuclear cells and platelets 
(Piel et al., 2014)and more recently in cancer cells(Bridges et al., 2014; Janzer et al., 
2014; Scotland et al., 2013; Wheaton et al., 2014). It has been reported that thistransient 
inhibition of complex 1 induces a drop in cellular energy charge, a measure of the 
energetic state of the cell defined as ([ATP] + 0.5[ADP])/([ATP] + [ADP] + [AMP]) 
(Foretz et al., 2010; Stephenne et al., 2011). The resulting fall in cellular ATP 
concentration and an increase in both ADP/ATP andAMP/ATP ratiosactivates the AMP-
activated protein kinase (AMPK),acritical energy sensor of cellular energy 
homeostasiswhich integrates multiple signaling networks to coordinate a wide array of 
compensatory, protective, and energy-sparing responses(Viollet et al., 2012). 
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Although the exact mechanism(s) by which metformin inhibits complex 1 
remains unknown, some studies were unable to detect a direct effect on isolated 
mitochondria except at very high concentrations, suggesting that the mitochondrial 
action of the drug requires intact cells(El-Mir et al., 2000; Guigas et al., 2004). On the 
other hand, it was recently reported that metformin (and other biguanides) can directly 
inhibit function of purified respiratory-chain complex 1, as well as in isolated 
mitochondria and submitochondrial particles from bovine heart{Andrzejewski, 2014 
#286}(Bridges et al., 2014), in line with previous data reporting similar properties using 
very high concentrations (20-100 mM) of the drug (Dykens et al., 2008; Owen et al., 
2000). However, it remains to be demonstrated if these mechanisms operate in vivo. 
It was also shown that the inhibitory effect of metformin on complex 1 was not 
prevented by nitric oxide (NO) synthase inhibitors or reactive oxygen species (ROS) 
scavengers (El-Mir et al., 2000), and was independent of AMPK, at least in primary 
mouse hepatocytes (Stephenne et al., 2011). Among the possible underlying 
mechanisms, it was proposed that the positive charge of metformin might account for its 
accumulation within the matrix of energized mitochondria, driven by the membrane 
potential (Owen et al., 2000). In addition, its apolar hydrocarbon side-chain would also 
promote its binding to hydrophobic structures, such as the constitutive phospholipids of 
mitochondrial membranes. Importantly, the lipophilicity of metformin, which is mostly 
due to its dimethyl-substituted terminal amino group, is much less than those of 
phenformin, which is more evenly distributed along its biguanide backbone. These 
peculiar physicochemical characteristics explain why two structurally-related 
biguanides affect differently the mitochondrial machinery, metformin being a weak but 
specific inhibitor of complex 1 whereas phenformin exerting a more potent but less 
specific action on the mitochondrial ETC (Drahota et al., 2014). It is also worth 
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mentioning that the inhibition of complex 1 activity by metformin is rather mild when 
compared to the reference inhibitor rotenone (El-Mir et al., 2000).Furthermore, 
metformin was shown to significantly reduce mitochondrial ROS production by selective 
inhibition of the reverse electron flow through the respiratory-chain complex 1, whereas 
rotenone triggers ROS production by increasing forward electron flow (Batandier et al., 
2006). Taken together, this suggests that their respective site of action on one or several 
of the subunits constituting the respiratory-chain complex 1 differ. Although recent 
studies have led to significant improvements in the understanding of its structure-
function relationships(Bridges et al., 2014),many aspects of the regulation of 
mitochondrial complex 1, such as the so-called active/deactive transition, remains 
incompletely understood. Further investigations are therefore still required to clarify 
the mechanism(s) by which metformin modulates the respiratory-chain complex 1 in 
such a unique way. Interestingly, it has been reported that direct binding of metformin 
to mitochondrial copper ions might be crucial for the metabolic effects of the drug 
(Logie et al., 2012). These findings point out again the crucial involvement of 
mitochondria in the molecular mechanism of action of metformin. Of note, not all the 
effects of biguanides are mediated by mitochondria since the glucose metabolism of 
erythrocytes, which are devoid of this organelle, was shown to be significantly affected 
secondary to metformin-induced change in cell membrane fluidity induced by the drug 
(Muller et al., 1997). 
 
Metformin and treatment of type 2 diabetes 
Metformin exerts its glucose-lowering effect primarily by decreasing hepatic 
glucose production through suppression of gluconeogenesis and enhancing insulin 
suppression of endogenous glucose productionand to a lesser extent, by reducing 
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intestinal glucose absorption and possibly improving glucose uptake and utilization by 
peripheral tissues, such as skeletal muscle and adipose tissue (Natali and Ferrannini, 
2006). Of note, it has been reported that metformin does not improve peripheral insulin 
sensitivity (Natali and Ferrannini, 2006) and improvements in insulin sensitivity in 
muscle may be related to the use of higher doses of metformin than clinically 
relevant.Additionally, metformin may also improve glucose homeostasis by interacting 
with the incretin axis through the action of glucagon-like peptide 1 (GLP-1) (Maida et al., 
2011; Mulherin et al., 2011).A recent study has found evidence that metformin and 
phenformin antagonize the action of the counter-regulatory hormone glucagon to 
suppress hepatic glucose production(Miller et al., 2013). Furthermore, Fullerton and 
colleagues recently showed that metformin-induced improvements in insulin action 
operatethrough alterations in hepatic lipid homeostasisvia theinhibitory 
phosphorylation of acetyl CoA carboxylase (ACC) by AMPK(Fullerton et al., 2013). 
 
Inhibition of hepatic gluconeogenesis 
An important breakthrough in the understanding of the molecular mechanism 
underlying metformin action was the demonstration that metformin-induced AMPK 
activation is associated with the inhibition of glucose production in primary hepatocytes 
(Zhou et al., 2001).The role for AMPK in mediating the action of metformin was initially 
supported by the reduction in metformin’s effect on glucose production in primary 
hepatocytes treated with compound C (Zhou et al., 2001), an AMPK inhibitor whichis 
now recognized to be non-selective. Thereafter, it was reported that, ablation of liver 
kinase B1 (LKB1, the upstream kinase that phosphorylates and activates AMPK)in the 
liver prevented the anti-hyperglycemic effects of metformin in high-fat fedmice (Shaw et 
al., 2005), also supporting the involvement of the kinase in the inhibition of glucose 
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production by the drug. In this study, it was shownthat LKB1/AMPK signaling controls 
the phosphorylation and nuclear exclusion of the transcriptional coactivatorcAMP-
response element-binding protein (CREB)-regulated transcription coactivator 2 (CRTC2, 
also known as TORC2)(Shaw et al., 2005), a pivotal regulator of gluconeogenic gene 
transcription in response to fasting.In addition, AMPK activation by metformin has also 
been reported to be involved in the transcriptional regulation of hepatic gluconeogenic 
enzyme genes by different mechanisms: i) dissociation of the CREB-CBP (CREB-binding 
protein)-TORC2 transcription complex, through the phosphorylation of the 
transcriptional coactivator CBP via atypical protein kinase C /λ (He et al., 2009), ii) 
increased expression of the orphan nuclear receptor small heterodimer partner (Lee et 
al., 2010), and iii) induction of SIRT1-mediated CRTC2 deacetylation(Caton et al., 
2010).However, the impact of reduction ingluconeogenic gene expression in metformin 
action has been recently disputed. Forced increase in gluconeogenic enzymes expression 
did not counteract the metformin-induced reduction in glucose output (Foretz et al., 
2010), this being in line with the emerging concept that transcriptional expression of 
PEPCK and G6Pase only weakly influences hepatic glucose output in patients with T2D 
(Samuel et al., 2009).  
Over the last years, controversy has arisen concerning the involvement of AMPK in the 
therapeutic effects of metformin on hepatic glucose production. Indeed, although 
metformin activates AMPK, this may not explain all of the therapeutic effects of the drug. 
Recent work in liver and primary hepatocytes from knockout models for both 
AMPK1/2 catalytic subunits and the upstream activating kinase LKB1 reveal that 
neither AMPK nor LKB1 are essential for metformin inhibition of hepatic glucose 
production (Foretz et al., 2010).However, a new report challenges these results and now 
shows that low concentrations of metformin suppress glucose production via AMPK 
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activation independently of an increase in the AMP/ATP ratio(Cao et al., 2014). A central 
question raised by this work is how does metformin activate AMPK without affecting 
energy charge.As described above, there is a consensus that metformin activates AMPK 
indirectly, secondary to the inhibition of the mitochondrial respiratory-chain complex 1, 
leading to ATP depletion and increase in AMP levels (Hawley et al., 2010). In addition, it 
has been suggested that perturbation of intracellular ATP levels, but not AMPK 
activationper se or inhibition of gluconeogenic gene expression, constitutes the critical 
factor underlying the effects of metformin on hepatic glucose output(Foretz et al., 2010). 
Gluconeogenesis is an energetically costly anabolic process, requiring 6 ATP equivalents 
per molecule of glucose synthesized, and it seems likely that the metformin-induced 
increase in AMP exerts a major role in the flux control of hepatic gluconeogenesis by the 
drug. Indeed, AMP is a potent allosteric inhibitor of fructose 1,6-bisphosphatase, a key 
enzyme in gluconeogenesis. Additionally, high AMP levels inhibit adenylatecyclase, 
thereby reducing cyclic AMP (cAMP) formation in response to glucagon and thus, fasting 
glucose levels (Miller et al., 2013).Taken together, a growing body of data indicates that 
multiple AMPK-independent regulatory points exist for direct AMP- and ATP-mediated 
effects of metformin on gluconeogenesis (Figure 1). In addition, it was very recently 
reported that the reduction in hepatic gluconeogenesis by metformin might result from 
a direct inhibition of the mitochondrial glycerophosphate dehydrogenase (mGPD), 
identifying another putative mitochondrial target of the drug (Madiraju et al., 
2014).Inhibition of mGPDhalts the glycerophosphate shuttle, blockinggluconeogenesis 
from glycerol and raising cytosolic NADH that feeds back on lactate dehydrogenase and 
also impairsincorporation of lactate into glucose. 
 
Regulation of lipid metabolism 
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Another effect of metformin is to improve lipid metabolism by reducing hepatic 
steatosisas demonstrated in rodent liver(Lin et al., 2000; Woo et al., 2014)and also 
reported in a clinical study (Marchesini et al., 2001). It was also recently reported that 
metformin exerts a beneficial effect on circulating lipids by lowering plasma 
triglycerides, through a selective increase in VLDL-triglyceride uptake and fatty acid 
oxidation in brown adipose tissue(Geerling et al., 2014). The metformin-induced 
reduction in tissue lipid storage is consistent with an increase in both fatty acid 
oxidation and inhibition of lipogenesis, presumably mediated by AMPK activation 
(Geerling et al., 2014; Zang et al., 2004; Zhou et al., 2001). Further support for a role of 
AMPK in the mechanisms of metformin action on lipid metabolism was recently 
provided inknock-in mouse models in which ACC1 and ACC2 were rendered insensitive 
to AMPK phosphorylation (Fullerton et al., 2013). These mice are refractory to the lipid-
lowering and insulin-sensitizing effects of metformin, showing that metformin-induced 
reduction in blood glucose levels depends on its ability to lower cellular fatty acid levels 
through the AMPK-dependent phosphorylation of ACC. Thus, the inhibition of hepatic 
glucose production by metformin may be, at least in certain conditions, secondary to the 
effects of the drugon ACC. These observations offer a potential explanation for the lack 
of metformin action on blood glucose levels in liver-specific LKB1-knockout mice fed on 
a high-fat diet (Shaw et al., 2005). Indeed, impaired metformin-induced AMPK 
phosphorylation in the absence of LKB1 would prevent ACC phosphorylation and the 
ability of metformin to improve insulin sensitivity and lower blood glucose.Therefore, 
metformin can acutely suppress hepatic glucose output by acting on distinct metabolic 
pathways via AMPK-independent and AMPK-dependent mechanisms in the context of 
insulin resistance (Figure 1). 
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Metformin action in cardiovascular system 
Metformin andcardioprotection 
Cardiovascular diseases are undoubtedly associated with T2D and ischemic heart 
disease is the main cause of death in type 2 diabetic population(Grundy et al., 1999). The 
cardiovascular dysfunctions associated with T2D are macro- and micro-vascular 
abnormalities including atherosclerosis of large arteries and coronary atherosclerosis 
which contributes to not only diabetes-related mortality and morbidity, but also include 
diabetic cardiomyopathy, a specific heart muscle dysfunction that occurs independently 
of coronary artery disease (Bugger and Abel, 2014). Although metformin is a first-line 
glucose-lowering pharmacological agent, its use was historically contraindicated in 
patients with heart failure due to concerns regarding increased risk of lactic acidosis. 
However, numerous studies revealed that metformin-associated lactic acidosis is 
minimaland that metformin treatment clearly reduces mortality and morbidity of type 2 
diabetic patients with cardiovascular diseases such as stable coronary artery disease, 
acute coronary syndrome and myocardial infarction (Eurich et al., 2013; Masoudi et al., 
2005). Currently, clinical practice guidelines recommend using metformin as first-line 
therapy in diabetic patients with heart failure(American Diabetes Association, 2014). 
The UKPDS trial nicely demonstrated that metformin was more effective than 
sulphonylurea or insulin in patients allocated to intensive blood-glucose control (1998). 
In this study, metformin significantly reduced all-cause mortality and diabetes-related 
death by 36% and 42%, respectively with a significant reduction in myocardial 
infarction events, which persisted after a 10-year follow-up (Holman et al., 2008; 1998). 
Numerous recent studies have confirmed the UKPDS conclusions. In these studies, 
metformin use was associated with better short- and/or long-term prognosis than other 
antidiabetic treatments in diabetic patients with acute coronary syndrome(Hong et al., 
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2013) or chronic heart failure (Eurich et al., 2013). However, it has to be noted that the 
benefit obtained with metformin in comparison to the other glucose-lowering agents is 
generally quite modest. Importantly, the use of metformin in non-diabetic patients 
suffering from coronary heart disease was not associated with any beneficial 
effects(Lexis et al., 2014; Preiss et al., 2014). Several meta-analyses have been recently 
performed (Boussageon et al., 2012; Eurich et al., 2013; Lamanna et al., 2011). Their 
inclusion criteria (only population at low risk of mortality; including or not patients with 
heart failure; including or not non-diabetic patients) and their conclusions slightly differ. 
The first concludes that metformin monotherapy improves survival whereas 
concomitant utilization with sulphonylurea was associated with reduced survival 
(Lamanna et al., 2011). In the second, the effectiveness of metformin to avoid death or 
cardiovascular events is not established by existing studies for the second meta-analysis 
(Boussageon et al., 2012). Finally, the more recent meta-analysis indicates that 
metformin treatment is associated with reduced mortality compared with controls and 
is at least as safe as other glucose-lowering agents in diabetic patients with heart failure 
(Eurich et al., 2013). Future clinical trials are clearly necessary to definitively conclude 
about the safety and cardioprotective effects of metformin treatment. 
 
Metformin in hypertension and atherogenesis 
The mechanisms involved in the beneficial cardiovascular effects of metformin in 
diabetic patients are not fully understood. A plausible explanation is the systemic anti-
hyperglycemic effect of the drug,whereby lowered gluconeogenesis decreases glucose 
levels and secondarily reduces insulin levels. However, several other molecular 
mechanisms directly targeting the cardiovascular system have been suggested by animal 
studies to participate in the benefits of metformin (Figure 2). A large part of these 
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effects appears to be mediated by AMPK. The activation of AMPK by metformin-induced 
energy stressis relevant to the vascular system, which is known to be alteredin diabetes 
by endothelial dysfunction and atherogenesis. Atherogenesisis accompanied by an 
impairment of endothelium-dependent relaxation, increased reactive oxygen species 
(ROS) production and reduced nitric oxide (NO) bioavailability, mediating pro-
inflammatory and pro-thrombotic mechanisms including platelet aggregation and 
leukocyte adhesion to the wall. Several cellular and animal studies have evaluated the 
potential anti-atherogenic action of metformin and AMPK activation. Metformin has 
been shown to inhibit high glucose-dependent ROS overproduction in aortic endothelial 
cells and its consequent endothelial dysfunction (Detaille et al., 2005; Ouslimani et al., 
2005). The decrease in ROS production is mediated by a double mechanism involving a 
reduction in NADPH oxidase activity and an inhibition of the respiratory-chain complex 
1. Two more recent studies proposed that AMPK mediates this metformin-induced 
NADPH oxidase inactivation reducing cytoplasmic ROS production (Batchuluun et al., 
2014; Bhatt et al., 2013). In parallel, Kukidome and colleagues showed that AMPK 
activation reduces the hyperglycemia-mediated mitochondrial ROS overproduction via 
the induction of manganese superoxide dismutase and the promotion of peroxisome 
proliferator-activated receptor-gamma coactivator-1alpha (PGC-1α)-dependent 
mitochondrial biogenesis in human umbilical vein endothelial cells (Kukidome et al., 
2006). AMPK activation is also known to induce endothelial NO synthase (eNOS) 
activation and NO-dependent vasodilation. In line with this action, it has been recently 
shown that metformin restores endothelial function through the inhibition of 
endoplasmicreticulum (ER) stress and oxidative stress and via the increase in NO 
bioavailability in obese diabetic mice, these effects being mediated by the 
AMPK/peroxisome proliferator-activated receptor  pathway (Cheang et al., 2014). In 
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addition, metformin targets advanced glycationend-products (AGEs), which are 
significant contributors of complications linked to diabetes. Indeed, metformin, 
independently of its anti-hyperglycemic property, is able to reduce AGEs synthesis and 
the expression of their specific cell receptor called RAGE in endothelial cells (Ouslimani 
et al., 2007). Finally, metformin treatment of patient with T2D was associated with a 
decrease in the level of the soluble intercellular adhesion molecule-1 (ICAM-1) and the 
soluble vascular cell-adhesion molecule-1 (VCAM-1), both being directly correlated to 
increase in cardiovascular events in such population (De Jager et al., 2005). 
Interestingly, as for AGEs, this decrease in ICAM-1 and VCAM-1 level was independent of 
the anti-hyperglycemic action of the drug.  
 
Metformin in myocardial injury 
The protective action of metformin also occurs at the myocardium and 
cardiomyocyte levels. Several ex vivo experiments using perfused heart protocols 
revealed a protective action of metformin during an ischemic episode. In a working-
heart perfusion model where metformin is administered before a mild ischemic episode, 
the anti-diabetic drug improved rat cardiac functional post-ischemic recovery 
(Legtenberg et al., 2002). It has been also shown that metformin given at the time of 
reperfusion reduced myocardial infarct size in both non-diabetic and diabetic hearts 
(Bhamra et al., 2008; Paiva et al., 2009). In these two last studies, the protective action of 
metformin was associated with a PI3K-mediated inhibition of the mitochondrial 
permeability transition pore opening and with increased intracellular formation of 
adenosine. However, the same group also showed that chronic metformin treatment of 
diabetic rats augments their myocardial resistance to ischemia-reperfusion injury via a 
pathway involving AMPK activation and PGC-1(Whittington et al., 2013). Similar 
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results have been obtained using in vivo models of myocardial infarction. In mice 
subjected to permanent left coronary artery occlusion or to one hour left coronary 
artery occlusion followed by reperfusion, 4 weeks metformin treatment improved 
survival and preserved left ventricular dimensions and left ventricular ejection fraction 
(Gundewar et al., 2009). These effects were concomitant to AMPK and eNOS activation, 
to increase in PGC-1 expression and disappeared in mice lacking AMPK or eNOS. In a 
similar study, Yin and colleagues demonstrated that metformin treatment increases 
AMPK activity, improves cardiac function and reduces infarct size after a myocardial 
infarction in rats (Yin et al., 2011). This protective action of metformin was also 
established in a dog model of heart failure (Sasaki et al., 2009). The authors nicely 
showed that other AMPK activators, such as 5-aminoimidazole-4-carboxamide 1--D-
ribofuranoside (AICAr), have the same effect than metformin, suggesting a role of this 
protein kinase. In cardiomyocytes, metformin reduced apoptosis by increasing anti-
apoptotic proteins and attenuating the production of pro-apoptotic proteins (Yeh et al., 
2010). These effects correlate with AMPK activation and can be reproduced by 
AICAr(Yeh et al., 2010). Metformin and AMPK also influence autophagy, which is known 
to be dysregulated in diabetic cardiomyopathy and heart failure. Indeed, metformin is 
able to restore impaired autophagy via the dissociation of Bcl-2 from Beclin1 in diabetic 
wild-type mice but not in cardiac-specific AMPK-dominant-negative transgenic diabetic 
mice(He et al., 2013; Xie et al., 2011). 
 
Metformin in cardiac hypertrophy 
Left ventricular hypertrophy is common among patients with T2D, who 
commonly have chronic hypertension. AMPK is a known inhibitor of cardiac 
hypertrophy via the negative regulation of protein synthesis (via mTOR inhibition) and 
  19 
of gene transcription including mitogen-activated protein kinase and calcineurin-
nuclear factor of activated T cells pathways (Horman et al., 2012). In agreement with the 
anti-hypertrophic action of AMPK, metformin inhibits cardiac hypertrophy in a rat 
model of pressure overload (transverse aortic constriction)(Zhang et al., 2011). Avery 
recent publication has reported that metformin protects against transverse aortic 
constriction-mediated cardiac hypertrophy independently of AMPK (Xu et al., 2014). 
 
Metformin in diabetic cardiomyopathy 
A healthy human heart produces around 5-6 kg of ATP each day to sustain its 
function, representing 20 times its own weight(Horman et al., 2012). This ATP is 
generated via the mitochondrial oxidation of fatty acids (for 70 %) and 
glucose/pyruvate (for 30 %). Fatty acids are preferred substrates because their 
oxidation inhibits glucose catabolism via the Randle cycle. However, in the postprandial 
state, insulin favors glucose utilization by promoting glucose uptake and glycolysis and 
inhibiting fatty acid oxidation. Currently, it is commonly accepted that this metabolic 
flexibility is essential for the maintenance of heart function. On the other hand, the 
metabolic inflexibility of diabetic hearts, which are insulin resistant and almost 
exclusively use fatty acids as source of energy, participates in the development of the 
diabetic cardiomyopathy (Bugger and Abel, 2014). Thus, therapies that promote glucose 
metabolism and normalize insulin sensitivity may reduce cardiac complications linked 
to diabetes. Metformin and AMPK are potential therapeutic candidates. Indeed, AMPK 
activation by metformin or other activators is able to stimulate cardiac glucose uptake 
and glycolysis independently of insulin, bypassing insulin resistance in insulin-resistant 
cardiomyocytes(Bertrand et al., 2006; Ginion et al., 2011). Even more interestingly, 
increase in AMPK activity by the same activators restored insulin sensitivity of insulin-
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resistant cardiomyocytes by a mechanism that still needs to be identified (Bertrand et 
al., 2006; Ginion et al., 2011). The concentration of metformin used in these acute (few 
hours) studies was however higher than those used in diabetic patients. We can 
postulate that lower concentrations of metformin could play similar role when utilized 
during longer time of exposure. In relation to the problematic of the effective dose of 
metformin in the heart, a new specific activator of AMPK (A-769662) has been recently 
shown to increase metformin sensitivity independently of the AMP/ATP ratio 
(Timmermans et al., 2014). Such compound might be useful clinically to increase 
metformin cardiac sensitivity. 
On the other hand, similarly to the situation found in endothelial cells (Detaille et 
al., 2005; Ouslimani et al., 2005), hyperglycemia induced NADPH oxidase-mediated ROS 
production and cell death in cardiomyocytes(Balteau et al., 2011). It is tempting to 
speculate that AMPK activation by metformin would be able to reduce this ROS 
production and to increase cardiomyocyte survival under hyperglycemic condition as 
demonstrated in the endothelium (Batchuluun et al., 2014; Bhatt et al., 2013). In 
agreement with this hypothesis, it has been recently shown that AMPK activation by A-
769662, the metformin analog phenformin or the new anti-diabetic drug glucagon-like 
peptide 1 limited glucotoxicity in adult cardiomyocytes(Balteau et al., 2014). The 
mechanism proposed in this study is the AMPK-dependent suppression of the 
hyperglycemia-mediated ROS production via the inhibition of the NADPH oxidase NOX2. 
 
Metformin in cardiac fibrosis 
Cardiac fibrosis is another element of diabetic cardiomyopathy and more 
generally heart failure. Interestingly, metformin is able to attenuate fibrosis in a canine 
model of heart failure,presumably via AMPK activation and its inhibitory action on 
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transforminggrowthfactor- (TGF-) expression (Sasaki et al., 2009). Similar results 
were obtained in mice subjected to left ventricular pressure overload by transverse 
aortic constriction even if, in this case, AMPK did not seem to be involved (Xiao et al., 
2010). In other studies, it has been established that metformin inhibits myofibroblast 
differentiation by suppressing ROS generation via the inhibition of the NADPH oxidase 
pathway (Bai et al., 2013), AMPK probably mediating this effect. Of note, a genetic link 
between AMPK and cardiac fibrosis has been recently demonstrated in a myocardial 
infarction mouse model(Noppe et al., 2014). 
 
Anti-neoplastic actions of metformin 
Pharmaco-epidemiology 
Pharmaco-epidemiologic evidence has played a major role in generating the 
hypothesis that metformin has utility in cancer prevention and/or treatment. A seminal 
report published in 2005 (Evans et al., 2005) presented evidence that diabetics treated 
with metformin had a substantially lower cancer burden than diabetics treated with 
other agents, and many other studies reached similar conclusions (Gandini et al., 2014). 
However, while results of certain studies are encouraging, there are contradictions in 
the available data and the hypothesis remains controversial (Tsilidis et al., 2014). 
Obviously, the populations under study were type 2 diabetic patients, and the 
conclusions may not be applicable to non-diabetic subjects, even if the conclusions were 
validated for diabetics. More importantly, all these studies are based on retrospective 
reviews of medical records, and are subject to a variety of potential biases(Suissa and 
Azoulay, 2014). On the other hand, some recent reports are consistent with the earlier 
pharmaco-epidemiologic data that provided evidence for reduced cancer burden among 
users of metformin. Examples include a study of multiple myeloma outcomes (Wu et al., 
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2014), one of prostate cancer risk based on the Danish cancer registry (Preston et al., 
2014), and one regarding prostate cancer prognosis (Margel et al., 2013). Thus, 
pharmaco-epidemiologic data have played an important role in generating the 
hypothesis that metformin may be useful in cancer prevention or treatment, but have 
not been consistent in supporting this concept. 
 
Indirect effects of metformin on cancer 
The proposed mechanisms of action of metformin relevant to oncology can be 
divided into two broad, non-mutually exclusive categories: effects on the host that 
indirectly influence the cancer, and direct effects on cancer cells (Pollak, 2012b) (Figure 
3). As noted earlier in this review, direct actions of metformin on the liver inhibit 
hepatic glucose production, resulting in systemic metabolic and endocrine effects that 
may influence cancer biology. The most obvious candidate change of oncologic relevance 
is the reduction of hyperinsulinemia, given prior evidence that high insulin levels can 
stimulate proliferation of a subset of common cancers(Pollak, 2012a). Importantly, 
however, the magnitude of metformin-induced decline in insulin levels is greater in type 
2 diabetics than in metabolically normal subjects and it is not clear if metformin-induced 
changes in plasma insulin levels, particularly in non-diabetics, are sufficient to perturb 
tumor biology. Nevertheless, there is evidence from a murine model that metformin 
administration is more effective with respect to tumor growth inhibition when diet-
induced obesity and hyperinsulinemia are present, and is associated with decreased 
activation of insulin receptors of cancer xenografts(Algire et al., 2011). Levels of 
variousadipokines relevant to cancer biology are also influenced by metformin in 
models, but further clinical data in this area are required. Also, a few studies have 
suggested immunological or anti-inflammatory actions of metformin (Moiseeva et al., 
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2013; Pearce et al., 2009) relevant to oncology, but there are to date no clinical data to 
support or refute these observations. Thus, the role of "indirect" actions of metformin 
remains an active research topic. 
 
Direct effects of metformin on cancer 
Dozens of in vivo and in vitro studies have shown direct anti-neoplastic activity of 
biguanides in model systems, but most of these have not provided mechanistic details 
nor considered dose-response issues relevant to clinical applications (Pollak, 2012b; 
Viollet et al., 2012). One of these (Huang et al., 2008) provided evidence that AMPK 
activation is important in the action of biguanides by showing that the direct AMPK 
activator A-769662 (which does not inhibit OXPHOS) has in vivo anti-neoplastic activity. 
Other observations suggest the relevance of inhibition of respiratory-chain complex 1 
within tumors underlies the therapeutic effect of metforminin vivo under conditions 
where dosing is adequate:a keyfinding was that tumor growth inhibition by metformin 
occurs under control conditions, but not when the tumor model is engineered to express 
the yeast metformin-resistant Saccharomyces cerevisiae NADH dehydrogenase NDI1 
protein (Birsoy et al., 2014; Wheaton et al., 2014). 
Alterations in cellular metabolism in a manner that is influenced by mutations in 
exposed cancer cells are important consequences of metformin-inducedreduction of 
oxidative phosphorylation(Buzzai et al., 2007). This suggests the possibility of rational 
drug combinations(Ben Sahra et al., 2010).Particularly interesting work has provided a 
metabolic rationale for combining biguanides with small molecule drugs that inhibit 
oncogenic kinases that drive glycolysis (Pollak, 2013b). These studies support the 
possibility that cancer cells have a requirement to increase OXPHOS, at least transiently, 
to compensate for the decreased glycolysis that arises as a consequence of oncogenic 
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kinase inhibition. In the presence of biguanides, this compensatory increase is 
attenuated, resulting in enhanced antineoplastic activity of the kinase inhibitor(Haq et 
al., 2013). Mutation of isocitrate dehydrogenase-1 (IDH-1) is an important topic in 
cancer metabolism, and there is preclinical evidence justifying study of the combination 
of a biguanide and inhibitors of mutated IDH-1 (Grassian et al., 2014). There is also 
evidence of a benefit of combining biguanides with conventional chemo- and radio- and 
hormonal therapies(Pollak, 2012b). 
An early finding supportinga direct action of metformin on cancer cells was the 
observation that the drug was growth inhibitory in vitro in a manner that was associated 
withAMPK activation and mTOR inhibition, as a consequence of metformin-induced 
energetic stress (Zakikhani et al., 2006). Further work in this direction showed that 
genetic ablation of the α1 catalytic subunit of AMPK accelerates Myc-induced 
lymphomagenesis, consistent with the observation that AMPK activation not only 
downregulatesmTOR, but also suppresses the excess aerobic glycolysis (Warburg effect) 
characteristic of most transformed cells (Faubert et al., 2013). This line of investigation 
suggests a tumor suppressor role for AMPK. 
However, it is now recognized that AMPK activation under conditions of 
energetic stress can improve cell survival(Jeon et al., 2012) by tuning cellular energy 
metabolism to reduce energy consumption, in keeping with the evolutionary role of 
AMPK in adjusting metabolism to cope with low nutrient supply. Thus, it remains to be 
determined if the anti-proliferative but pro-survival consequences of AMPK activation in 
cancer cells, either due to the inhibition of oxidative phosphorylation by metformin or 
the direct activation by specific pharmacological activators,will be of clinical benefit. 
Consideration of the consequences of biguanide-induced energetic stress in 
cancer cells defective in AMPK activation is of particular interest. Xenograft(Algire et al., 
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2011) and transgenic (Shackelford et al., 2013) models have shown that cancers with 
loss of function of LKB1are hypersensitive to biguanides. This observation is consistent 
with the notion that activation of AMPK, while associated with reduction in 
proliferation, actually mitigates energetic stress induced by metformin by reducing 
energy consumption, thereby favoring cell survival. Cancer cells functionally deficient in 
AMPK, in contrast, will be less likely to reduce energy consumption in face of biguanide-
induced reduction in ATP generation, and therefore more likely to experience a lethal 
energetic crisis. This scenario is attractive because it implies a favorable therapeutic 
index (a greater effect on the cancer than the normal host tissues), as AMPK-defective 
cancers would be more sensitive to biguanides than normal tissues that retain a 
functional AMPK signaling system. This situation may be relevant to a sizable proportion 
of human cancers: for example, more than a third of non-small cell lung cancers are 
reported to be LKB1-defective. Cancers with mutations in genes encoding respiratory-
chaincomplex 1 components have also been shown to be hypersensitive to 
biguanides(Birsoy et al., 2014). 
 Collectively, pre-clinical studies raise enthusiasm for clinical trials of metformin, 
in a manner that is less controversial than the pharmaco-epidemiologic rationale. 
However, it is clear that precise mechanisms have not been defined, and it is important 
to point out that in order for metformin to have a direct anti-neoplastic effect, an 
adequate drug concentration must be achieved in neoplastic tissue. This concentration 
will be determined not only by the plasma level, which is related to the administered 
dose and to pharmacokinetic variables, but also to cellular uptake in cancer cells which 
may vary with respect to expression of OCT1 and other relevant transporters. The 
serum levels of metformin achieved in diabetic patients and in many in vivo models (as 
reviewed above) are in the micromolar range, while growth inhibition in vitro is usually 
  26 
observed at millimolar concentrations. Thus, an overarching research question is what 
metformin concentrations are achieved in neoplastic tissue of patients receiving 
conventional anti-diabetic doses of metformin. Even before consideration of tumor 
biology, there may well be heterogeneity between cancer patients with respect to direct 
actions of metformin that arise as a consequence of whole organism and cellular 
pharmacokinetic factors. Imprecision regarding achieved drug levels in target tissues in 
preclinical models that demonstrate antineoplastic activity makes extrapolation to the 
clinic hazardous: it remains uncertain if the laboratory data should be used to support 
clinical trials of conventional anti-diabetic doses of metformin or clinical trials of more 
aggressive and novel methods of biguanide administration designed to maximize tumor 
drug concentration.  
 
Clinicaladvances and outlook 
While many clinical trials are ongoing, few actual clinical outcome results have been 
reported to date. However, there have been many publications of pilot studies that refer 
to surrogate endpoints such as changes in tumor proliferation rate between serial tumor 
biopsies obtained from patients prior to and during metformin exposure. Many of these 
have shown encouraging decreases in proliferation in breast, prostate, and endometrial 
cancers(Pollak, 2012b; Viollet et al., 2012), but overall results have been difficult to 
interpret because the magnitude of declines is in many cases smaller than those 
associated with currently approved treatments, and because in some studies declines 
are confined to subsets of patients. It should be noted that the design of ongoing 
randomized clinical trials may not address some of the specific contexts suggested to be 
of high interest by pre-clinical work performed only after the trials were designed, such 
as strategic combinations of biguanides with tyrosine kinase inhibitors (Pollak, 
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2013b)or selective use of biguanides for tumors with respiratory-chaincomplex 
1mutations(Birsoy et al., 2014). 
Anecdotal clinical evidence of stimulation of glucose uptake by intestinal mucosa 
by metformin has been presented in the nuclear medicine literature (Gontier et al., 
2008). While from a radiologic perspective this was reported as a bothersome artifact, 
from a physiologic perspective, the data may represent pharmacodynamic evidence of 
biguanide-induced inhibition of OXPHOS in intestinal mucosa, leading to energetic stress 
and a compensatory increase in glycolysis, resulting in the observed increase in glucose 
uptake. This may take place preferentially in bowel as compared to other tissues 
because of the high luminal concentration of metformin following oral administration, 
emphasizing the importance of pharmacokinetic factors in determining tissues where 
direct biguanide actions are likely to occur. These data are correlated with greater 
reductions of proliferation rate by metformin in colon (Pollak, 2013a) than in most 
other tissues examined, and reduced aberrant crypt foci in patients (Hosono et al., 
2010), thus raising the possibility of specific applications for metformin in colorectal 
cancer prevention. 
 Ongoing research comprises two broad areas. One examines the hypothesis that 
metformin, when administered in the manner used for diabetes therapy, has utility for 
cancer prevention or treatment. There has been relatively little effort to address this 
possibility in a quantitative fashion in preclinical model systems because it is difficult to 
accurately simulate human pharmacokinetics following oral dosing in rodents, and 
because there has been enthusiasm among physicians to proceed directly to human 
studies (Pollak, 2014). Thus, there are more than 200 Oncology clinical trials involving 
metformin in progress. Another research area, which has not yet led to clinical trials, 
involves optimization of biguanide pharmacokinetics to maximize exposure of 
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neoplastic tissue. This work is based on one hand on the attractive laboratory data 
related to the ‘direct’ mechanism of action, and on the other hand on concern that 
conventional anti-diabetic dosing may be inadequate for the desired effects. Relative to 
metformin, phenformin or novel biguanides(Narise et al., 2014) may have reduced 
requirements for cell surface transporters to enter cancer cells or other desirable 
pharmacokinetic properties.This has been clearly evidenced in rat hepatoma cells H4IIE, 
where quinidine, a competitive OCT1 inhibitor, completely blocked AMPK activation by 
metformin, while AMPK activation byphenforminandgalegine was notaffected (Hawley 
et al., 2010). Metformin may have very different effects if given parentally rather than 
orally. However, while such approaches may have advantages, they also may be 
associated with unacceptable toxicity, so that conventional preclinical work leading to 
phase I safety and dose finding clinical trials would be required as a first step. 
 
Conclusionand therapeutic perspectives 
After more than 50 years of clinical experience, the utility of metformin in the control of 
hyperglycemia in T2D has been well established. The safety of metformindifferentiated 
it fromphenformin and buformin,which were withdrawn in most countries due to a 
higher risk incidence of lactic acidosis. The favorable risk/benefit profile of metformin 
hasmade it one of the most widely prescribed drugs in the world.Clinically, metformin 
exerts its anti-hyperglycemic effect mostly through the inhibition of hepatic 
gluconeogenesis. Its primary site of action is the mitochondria via its mild and specific 
inhibition of the respiratory-chain complex 1, thereby lowering energy charge and 
ultimately leading to a reduction in hepatic glucose output. Although the energy sensor 
AMPK is activated by a decrease in the cellular energy charge, it appears to be 
dispensable for the direct inhibitory effect of metformin on hepatic gluconeogenesis, but 
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still may indirectly inhibit by restoring hepatic insulin sensitivity. This is consistent with 
the role of AMPK in the lipid-lowering effects and improvements in insulin sensitivity by 
metformin in the liver. Recent advances revealed a new molecular target in the 
mitochondria with the direct inhibition of mGPD, resulting in altered cellular redox state 
and limitinglactate and glycerol contribution to hepatic gluconeogenesis. 
The evidence presented in this review suggests that metformin may have clinical 
value in the treatment of cardiovascular complications associated with T2D by exerting 
a variety of cellular actions in different tissues and cell types. Chronic metformin 
treatment of patients leads to a basal state of cardioprotection, thereby potentially 
limiting the occurrence of myocardial infarction, heart failure, diabetic cardiomyopathy 
and cardiac hypertrophy. Multiple molecular mechanisms were proposed including 
reduction of ER stress, oxidative stress, apoptosis, protein synthesis and insulin 
resistance in endothelial cells, cardiomyocytes and cardiac fibroblasts through AMPK-
dependent and AMPK-independent pathways.  
Some studies have raised the possibility that metformin may also be effective in 
providing protection against cancer.The concept of 'repurposing' metformin for cancer 
prevention or treatment is appealing (Pollak, 2014), as the drug is inexpensive and well 
tolerated relative to commonly used anti-neoplastic agents. The original and most 
optimistic hypothesis, that this drug at conventional anti-diabetic doses is useful for a 
wide variety of indications in oncology, was based in part on pharmaco-epidemiologic 
data that are now considered controversial. As most experimental evidence for anti-
neoplastic activity of metformin involves drug exposure levels considerably higher than 
those in serum of metformin-treated diabetics, the use of novel metformin dosing 
strategies, including intravenous rather than oral administration, as well as the use of 
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phenformin or novel biguanides designed to have pharmacokinetic characteristics 
optimized for oncologic indications may be worthwhile. 
Furthermore, pre-clinical studies have identified not only rational drug 
combinations involving biguanides that deserve evaluation but also specific tumor 
characteristics, such as mutations of STK11/LKB1, that may be associated with 
biguanide sensitivity. Therefore, even if the first generation of metformin trials for 
cancer treatment are disappointing, there will be interesting questions to address in 
subsequent studies. On the other hand, demonstration of clinical benefit of any of the 
ongoing trials would represent an important example of productive ‘repurposing’ 
research, and lead to efforts to build on that success. 
Among clinicians, metformin is regarded as a widely used and "mature" generic 
drug with a well-established and important role in treatment of T2D, for which there is a 
limited research agenda remaining. However, as reviewed here, from a mechanistic 
perspective, there are many important unanswered questions (Table 1), and a 
recognition that biguanides have unique therapeutic properties arising from their 
effects on cellular energy metabolism. It is possible that further understanding of the 
mechanistic aspects of biguanide pharmacology will result in advances in treatment not 
only of diabetes, but also in cardiovascular and neoplastic diseases. 
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Table 1: Examples of challenges in biguanide research 
Elucidate the precise mechanism(s) by which metformin interacts with and inhibits the 
mitochondrial respiratory-chain complex 1 
Clarify the effect of metformin on tissue-specific regulation of mitochondrial biogenesis and its 
subsequent impact on cellular energy homeostasis 
Clarify if metformin actually acts as an "insulin sensitizer" in vivo, or if the reduction of insulin 
level associated with use of the drug is completely accounted for by decrease in glucose 
secondary to decrease gluconeogenesis 
Define mechanisms that limit duration of efficacy of metformin in treatment of type 2 diabetes 
Clarify why cardiac benefits of metformin are greater in diabetics than non-diabetics 
Provide clinical evidence for or against clinical anti-neoplastic action of metformin in diabetic 
and non-diabetic cancer patients 
Define optimum dosing of biguanides for cancer treatment in diabetic and non-diabetic patients 
and establish if phenformin or novel biguanides offer advantages for cancer treatment 
Delineate the role of AMPK in metformin action in different tissues and different disease states 
Design and evaluate rational combinations of metformin with other pharmacological agents for 
various indications 
Understand the genetic influences on efficacy of metformin for various indications and move 
towards personalized medicine to optimize therapies 
Are recently described actions of metformin on the intestinal microbiome(Cabreiro et al., 2013) 
relevant to any of the clinical effects of the drug ? 
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Figure legends: 
Figure 1: Molecular mechanisms of metformin-induced inhibition of hepatic 
glucose output. 
Metformin is transported into hepatocytes mainly through OCT1 and partially inhibits 
mitochondrial respiratory-chain complex 1, resulting in reduced ATP levels and 
accumulation of AMP. Gluconeogenesis is reduced as a result of ATP deficit limiting 
glucose synthesis, increased AMP levels leading to reduced activity of the key 
gluconeogenic enzyme FBPase, inhibition of adenylatecyclase and cAMP-PKA signaling, 
and inhibition of mGPD contributing to altered redox state and reduced conversion of 
glycerol to glucose. Metformin-induced change in AMP/ATP ratio also activates AMPK, 
which suppresses lipid synthesis and exerts insulin sensitizing effects.Abbreviations: 
ACC, acetyl CoA carboxylase; AMPK, AMP-activated protein kinase; cAMP, cyclic AMP; 
complex 1, respiratory-chaincomplex 1; DHAP, dihydroxyacetone phosphate; FBPase, 
fructose-1,6-bisphosphatase; G3P, glycerol-3-phosphate; cGPD, cytosolic 
glycerophosphate dehydrogenase; mGPD, mitochondrial glycerophosphate 
dehydrogenase; OCT1, organic transporter 1; PKA, protein kinase A. 
 
Figure 2: Main putative molecular mechanisms involved in the cardioprotective 
effects of metformin. Animal and in vitro studies proposed a protective action of 
metformin against several cardiovascular diseases linked to T2D including myocardial 
infarction, hypertrophy and diabetic cardiomyopathy, which lead to cardiac dysfunction 
that could evolve to heart failure. The molecular mechanisms involved in this protection 
are multifaceted targeting endothelial, cardiomyocyte and fibroblast (dys)functions. 
More details are given in the text.Abbreviations: AGEs, advancedglycation end-products; 
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AMPK, AMP-activated protein kinase, eEF2K, eukaryotic elongation factor 2 kinase; 
eNOS, endothelialnitricoxidesynthase; ER, endoplasmicreticulum; ICAM-1, 
intercellularadhesion molecule-1; MAPK, mitogen-activated protein kinase; MnSOD; 
Manganese superoxide dismutase; mPTP, mitochondrial permeability transition pore; 
mTOR, mammalian target of rapamycin; NFAT, calcineurin-nuclear factor of activated T 
cells; NOX, NADPH oxidase; PGC-1α, peroxisomeproliferator-activatedreceptor-gamma 
coactivator-1alpha; ROS, reactiveoxygenspecies; TGF-β, transforminggrowth factor-β; 
VCAM-1, vascularcelladhesion molecule-1. 
 
Figure 3: Proposed mechanisms by which biguanides may influence cancer 
biology. These mechanisms may be indirect, where the drug does not interact with the 
cancer cells, but rather alters the endocrine-metabolic milieu of the host in a way that 
may influence cancers. Indirect effects include but are not confined to suppression 
ofgluconeogenesis and decreased systemic glucose and insulin levels. The insulin-
lowering effect of metformin is used as an example; other indirect mechanisms have 
been proposed. Direct interactions between biguanides and cancers are supported by 
recent experimental data and occur when drug exposure is adequate to induce energetic 
stress in cancer cells. There is uncertainty if conventional anti-diabetic doses of 
metformin are sufficient to accomplish this.  Genetic characteristics of a cancer likely 
influence not only the extent to which biguanides accumulate, but also its ability to deal 
with energetic stress, and thus the degree of therapeutic benefit. Abbreviations: GI, 
gastrointestinal; LKB1, liver kinase B1; OXPHOS, oxidative phosphorylation. 
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